Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function

  • STATUS
    Recruiting
  • End date
    Jan 1, 2027
  • participants needed
    100
  • sponsor
    National Institute of Environmental Health Sciences (NIEHS)
Updated on 24 October 2022
bronchoscopy
respiratory disease
Accepts healthy volunteers

Summary

Background

Respiratory diseases affect more than 1 billion people worldwide. They are a growing public health concern. The lungs are constantly exposed to environmental factors such as dust, fumes, microbes, and pollutants. But much is still not known about how these pollutants lead to respiratory illnesses. Researchers want to collect samples from lungs and blood to see how genetics and environmental pollutants affect cellular responses or functioning.

Objectives

To study how cytochrome P450 epoxygenase pathway enzymes affect macrophage function in the lungs and inflammatory responses.

Eligibility

Adults ages 18 65 who can have a bronchoscopy.

Design

All study visits will take place at the NIEHS Clinical Research Unit in Research Triangle Park, NC.

At study visit 1, participants will be screened with medical history and physical exam. They will have blood and urine tests. They will take tests that measure their lung function. They will answer questionnaires. Before the visit, they will be given a list of medicines they cannot take. They also must not have caffeine on the day of their visit. The visit will last about 3 hours.

At study visit 2, participants will give blood samples. They will undergo bronchoscopy. For this, they will get an intravenous line in a vein to get sedatives. Their airways will be numbed. Cells will be collected from their lungs. They will fast for 8 hours before the visit. They must have someone else drive them home from the visit. The visit will last about 3-4 hours.

Participants will get a follow-up phone call about 1 day after study visit 2.

Description

This is a prospective, cross-sectional study designed to provide a consistent method for obtaining biological samples and respiratory health-related information from participants for use in research that evaluates lung function (e.g., responses to environmental agents such as air pollution particles, engineered nanomaterials, or immune ligands; the role of genetics on cellular responses or functioning).

Study participants will be adult volunteers, ages 18-65 (inclusive), who meet eligibility criteria to undergo bronchoscopy. Potential participants will be prescreened and scheduled for a final eligibility visit that will include medical history review, vital signs, physical examination, blood draw, and pulmonary function tests. After eligibility is confirmed, the participant will be scheduled for biological sample collections, which will include a blood draw and bronchoscopy.

The objective of this protocol is to investigate the role of cytochrome P450 (CYP) epoxygenase pathway enzymes, including the soluble epoxide hydrolase (sEH; encoded by EPHX2) and CYP2J2 proteins, in macrophage function and inflammatory responses. The primary outcome measure will evaluate macrophage phagocytosis in an ex vivo assay, comparing groups of individuals with and without EPHX2 and CYP2J2 polymorphisms of interest. Secondary outcomes will include evaluations of ex vivo gene expression of inflammatory receptors and cytokines in stimulated macrophages (alveolar and peripheral blood monocyte-derived), assessment of the lower airway microbiome from bronchoalveolar lavage (BAL) fluid, and measurement of eicosanoids and cytokines in serum and BAL fluid.

Details
Condition Polymorphism, Lung Inflammation
Clinical Study IdentifierNCT02743468
SponsorNational Institute of Environmental Health Sciences (NIEHS)
Last Modified on24 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 to 65 years, inclusive (males and females)
Able to travel to the NIEHS CRU for required study visits
Able to present a valid government-issued form of identification for entry to the NIEHS campus
Able to fast for 8 hours prior to the visit where bronchoscopy occurs
Has a responsible party who is willing and able to attend Visit 2 and drive the participant away from the CRU after completion of Visit 2, if the participant elects to undergo conscious sedation
Genotype information available for relevant CYP2J2 and EPHX2 polymorphisms, which
indicates
Wild type with respect to EPHX2 K55R, EPHX2 R287Q, and CYP2J27; or
Homozygous for EPHX2 K55R (wild type for the other SNPs); or
Homozygous for EPHX2 R287Q (wild type for the other SNPs); or
Homozygous for CYP2J27 (wild type for the other SNPs)

Exclusion Criteria

Current pregnancy or lactation, as medications used during the bronchoscopy can be excreted in the breast milk of lactating mothers
Current smoker or significant second-hand smoke exposure (defined by urine cotinine >200 ng/mL at screening)
Post-bronchodilator FEV1 < 70% of predicted
For asthmatics, any indication of moderate or severe asthma such as
Physician-directed emergency treatment for an asthma exacerbation within the preceding 12 months
Any use of systemic steroid therapy during the last year or continuous use of inhaled steroids over a period of 1 month or longer during the past 6 months
Regular use of cromolyn (except for prophylaxis of exercise induced bronchospasm) or any use of leukotriene inhibitors (Montelukast or Zafirlukast) within the past month
Symptoms including
Night-time symptoms of cough or wheeze greater than 1x/week
Exacerbations of asthma more than 2x/week
Daily requirement for albuterol due to asthma symptoms (cough, wheeze, chest tightness)
Bleeding disorders or regular use of aspirin or other non-steroidal anti-inflammatory
drugs (which inhibit platelet function) or other drugs that prolong bleeding
time such as warfarin, heparin or derivatives, or clopidogrel and related ADP
inhibitors
Sickle cell disease or GP6 deficiency
Facial deformity or major facial surgery
Asthma exacerbation or respiratory infection 4 weeks prior to study visit
Allergy or history of adverse reactions to lidocaine, midazolam, or fentanyl
Vital signs (temperature, blood pressure, pulse rate) that are outside of the established CRU limits
Body weight <50 kg (<110 lbs)
The following abnormal clinical laboratory values (obtained during Visit 1 assessment)
Platelet count <100,000 per L
White blood cells count <3000 per L
Absolute neutrophil count <1000 per L
Hematocrit <35% for both female and male
PT/INR and PTT based on reference laboratory established reference ranges
Serum creatinine >1.4 mg/dL
Any condition that, in the investigator's opinion, places the participant at undue
risk for complications associated with required study procedures
Use of the medication colchicine (commonly used to treat gout attacks) in the past 2 weeks
Volunteers meeting any of the below temporary exclusions may enroll in the study, but may
not
undergo the bronchoscopy procedure within the time frames specified for each below
temporary exclusion. If any of the following conditions are met, the bronchoscopy will be
rescheduled such that none of these temporary exclusions apply
Temp. EXCL 1. An asthma exacerbation requiring increased asthma medications for more than 1
day (and other than exercise-induced asthma) within 1 month of bronchoscopy
Temp. EXCL 2. Viral upper respiratory tract infection or any acute infection requiring
antibiotics within 4 weeks of bronchoscopy
Temp. EXCL 3. Use of anti-inflammatory medications (including over-the-counter
preparations) during the 48 hours prior to the bronchoscopy and aspirin during the 14 days
prior to bronchoscopy
Temp. EXCL 4. Any food or fluids for 8 hours prior to the bronchoscopy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note